Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers
- PMID: 1683835
- DOI: 10.1007/BF00265912
Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers
Abstract
The pharmacokinetics of a single i.v. dose of dl-bisoprolol 0.16 mg.kg-1 ideal body weight has been studied in 8 obese women (mean weight 91 kg; 161% of ideal body weight) and 8 non-obese women (51 kg; 94% of ideal body weight). Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1). There was a negative correlation between Vz l.kg-1 and the percentage of ideal body weight (r = -0.672). Total body clearance was increased, but t1/2 and renal clearance was unchanged. It is concluded that tissue diffusion of bisoprolol in obese subjects is limited, despite its lipophilicity, possibly because of alteration in the blood flow to adipose tissue produced by bisoprolol.
Similar articles
-
Clinical pharmacokinetics of drugs in obesity. An update.Clin Pharmacokinet. 1993 Aug;25(2):103-14. doi: 10.2165/00003088-199325020-00003. Clin Pharmacokinet. 1993. PMID: 8403734 Review.
-
[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].Bull Acad Natl Med. 1990 Oct;174(7):959-67; discussion 967-8. Bull Acad Natl Med. 1990. PMID: 1981983 French.
-
Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.Br J Clin Pharmacol. 1997 Jun;43(6):563-70. doi: 10.1046/j.1365-2125.1997.00609.x. Br J Clin Pharmacol. 1997. PMID: 9205815 Free PMC article. Clinical Trial.
-
Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers.J Cardiovasc Pharmacol. 1991 Jul;18(1):28-34. doi: 10.1097/00005344-199107000-00005. J Cardiovasc Pharmacol. 1991. PMID: 1719288 Clinical Trial.
-
Effects of obesity on pharmacokinetics implications for drug therapy.Clin Pharmacokinet. 2000 Sep;39(3):215-31. doi: 10.2165/00003088-200039030-00004. Clin Pharmacokinet. 2000. PMID: 11020136 Review.
Cited by
-
What is the best size descriptor to use for pharmacokinetic studies in the obese?Br J Clin Pharmacol. 2004 Aug;58(2):119-33. doi: 10.1111/j.1365-2125.2004.02157.x. Br J Clin Pharmacol. 2004. PMID: 15255794 Free PMC article. Review.
-
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Acta Pharmacol Sin. 2012 Nov;33(11):1359-71. doi: 10.1038/aps.2012.103. Epub 2012 Oct 22. Acta Pharmacol Sin. 2012. PMID: 23085739 Free PMC article.
-
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7. Crit Care. 2021. PMID: 34112223 Free PMC article.
-
Clinical pharmacokinetics of drugs in obesity. An update.Clin Pharmacokinet. 1993 Aug;25(2):103-14. doi: 10.2165/00003088-199325020-00003. Clin Pharmacokinet. 1993. PMID: 8403734 Review.
-
Impact of obesity on drug metabolism and elimination in adults and children.Clin Pharmacokinet. 2012 May 1;51(5):277-304. doi: 10.2165/11599410-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22448619 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical